Stifel analyst Jonathan Block lowered the firm’s price target on Beta Bionics (BBNX) to $22 from $25 and keeps a Buy rating on the shares. Q4 results included “few surprises,” says the analyst, who sees an “upward bias” to initial 2026 guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Hold Rating Maintained as In-Line Results and Improving Margins Offset Near-Term Prescription Headwinds
- Beta Bionics sees FY26 revenue $130M-$135M, consensus $132.68M
- Beta Bionics reports Q4 EPS (30c), consensus (38c)
- Is BBNX a Buy, Before Earnings?
- Oracle gets upgrade and downgrade: Wall Street’s top analyst calls